Foundayo
Definition
Brand name for orforglipron, Eli Lilly's once-daily oral GLP-1 receptor agonist. The first non-peptide oral GLP-1 agonist to receive FDA approval (April 2026), with no food or water timing restrictions.
Foundayo (orforglipron)
Foundayo is the brand name for orforglipron, an oral non-peptide GLP-1 receptor agonist developed by Eli Lilly. It received FDA approval on April 1, 2026, for the treatment of obesity and overweight in adults, becoming the first oral non-peptide GLP-1 receptor agonist to reach the market.
Foundayo’s distinguishing feature is its molecular design: unlike all previously approved GLP-1 receptor agonists (including the only previous oral GLP-1 agonist, Rybelsus oral semaglutide), orforglipron is a small-molecule non-peptide. This design enables oral bioavailability without the absorption-enhancing technology and strict fasting conditions that oral semaglutide requires. Foundayo can be taken any time of day, with or without food or water.
Clinical efficacy from the Phase 3 ATTAIN program showed up to -12.4% mean weight loss at the 17.2 mg dose over 72 weeks under the treatment-regimen estimand. This is meaningfully lower than retatrutide’s Phase 3 weight loss (-28.3% in TRIUMPH-1 at 12 mg) but substantially exceeds historical anti-obesity medications other than the GLP-1 class.
Availability and pricing at launch: distributed through LillyDirect from April 6, 2026, at approximately $25 per month for commercially insured patients and $149 per month for self-pay patients. Eli Lilly has stated intent to file an additional application for orforglipron as a treatment for type 2 diabetes based on the Phase 3 ACHIEVE program. In Eli Lilly’s broader obesity portfolio, Foundayo is positioned as the accessible oral option, with Zepbound (tirzepatide) as the established injectable and retatrutide as the still-investigational maximal-efficacy candidate.